Created in 2013, ALCEDIAG is a personalized medicine company specializing in the development of diagnostics tests and clinical biomarkers with a primary focus on mental health and “precision psychiatry”.
ALCEDIAG has developed different signatures of blood biomarkers based on analysis of RNA editing, an epigenetic mechanism, combined with Artificial Intelligence algorithms. The first product of ALCEDIAG is Edit-B, a blood test to differentiate bipolar depression from unipolar depression.